Business
The Benefits and Significance of IB Neuro
The Benefits and Significance of IB Neuro.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n \n \n \n RNS Number : 0198A\n IQ-AI Limited\n 24 September 2020\n \n \n \n \n IQ-AI Ltd\n \n \n (\"IQ-AI\" or the \"Company\")\n \n \n The benefits and significance of IB Neuro\n \n \n \n \n \n \n \n IB Neuro, the flagship brand of IQ-AI's subsidiary Imaging Biometrics (\"IB\"), was the first commercially available dynamic susceptibility contrast (\"DSC\") perfusion approach and remains the only platform that automatically generates quantitative output; output that has been spatially validated with biopsy samples by multiple groups and enables objective longitudinal monitoring of treatment. In June of this year, Neuro Oncology published their consensus recommendations for the DSC MRI protocol available in IB Neuro™. This recommended protocol was the outcome of a large subcommittee of the Jumpstarting Brain Tumour Drug Development Coalition and provided evidence-based Best Practices for routine clinical use. \n \n \n \n \n \n Being the acknowledged standard in dynamic susceptibility contrast imaging is a notable milestone. MR DSC is the most common perfusion technology used for the evaluation of brain tumours, but most sites have yet to adopt or have as yet fully comprehended the value of having proven quantitative biomarkers available for brain tumour assessment. \n \n \n \n \n \n The post-processing of DSC data has evolved since the inception of IB in 2007. Now fully automated, a full array of perfusion parameter maps is generated within seconds. In addition, exclusively licensed technology transforms the inherently variable MR data to a fixed and known scale. This approach, demonstrated to be superior to various tissue normalisation approaches, quantifies output values across scanner vendors, field strengths, patients, and timepoints and allows for longitudinal comparison. Moreover, IB remains focused on advancing the field of MR DSC imaging, as recently evidenced by receiving two major NIH grants. Together, with an outstanding team of clinical and scientific collaborators, IB is well-positioned to further its lead in brain tumour imaging and treatment monitoring and apply those learnings to other cancers and pathologies beyond the brain, setting new standards.\n \n \n \n \n \n In the last 18 months, the team at IB has ported its core processing libraries, including the DSC technology in ...